- The stock price of Applied DNA Sciences (APDN) increased by 46.43% in the previous trading session. These are some details you should know.
The stock price of Applied DNA Sciences (APDN) – a leader in polymerase chain reaction (PCR)-based technologies – increased by 46.43% in the previous trading session. This is a continuation of momentum as the stock price increased by 494.2% over the past week.
Investors have been responded positively to Applied DNA Sciences announcing that its wholly-owned clinical laboratory subsidiary Applied DNA Clinical Labs, LLC (ADCL) has initiated analytical validation of a company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus.
This test has been developed as a type of NYSDOH Laboratory Developed Test (LDT). And if the test is validated by ADCL, a validation package will be submitted to the New York State Department of Health (NYSDOH) for approval. If approved, then the test will be used to power ADCL’s monkeypox testing services.
ADCL’s monkeypox test utilizes an A17L gene-target specific to monkeypox that enables the qualitative detection and differentiation of monkeypox virus from other non-variola orthopoxviruses using real-time PCR. And if validated and approved, then testing will be performed at ADCL’s CLEP/CLIA molecular diagnostics laboratory in Stony Brook, N.Y., utilizing its established and proven workflows to ensure accurate results and competitive turn-around-times.